TGA / PMDA / NMPA · Asia-Pacific
regimen — TGA / PMDA / NMPA regulatory status
regimen regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 52 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| CL3-95031-007 | Phase 3 | George Institute for | 2023-508507-20-00 |
| CMF regimen | Phase 3 | United Therapeutics Europe | NCT00002582, NCT00033683 |
| DIDaC/ NVALT35 | Phase 3 | Disc Medicine | 2025-520792-67-00 |
| DLY201619 | Phase 3 | Chinese Academy of | NCT02974426 |
| Decitabine plus HAAG regimen | Phase 3 | First People's Hospital | NCT04087967 |
| IAC regimen | Phase 3 | First People's Hospital | NCT02323022 |
| 2023-SR-002 | Phase 2 | First People's Hospital | NCT05774028 |
| 209628 | Phase 2 | GSK Glaxo Smith | 2023-508213-16-00 |
| ADCETRIS 50 mg powder for concentrate for solution for infusion | Phase 2 | Takeda | 2023-506415-18-00 |
| AVTX-009 Regimen 1 | Phase 2 | Avalo Therapeutics | NCT06603077 |
| All-trans Retinoic Acid in combination with the KPD Regimen | Phase 2 | First People's Hospital | NCT06158412 |
| Apatinib | Phase 2 | First People's Hospital | NCT03650738 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 20260060930 | New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases | US |
| 12410153 | Compounds, compositions and methods | US |
| 12390463 | Dosage forms and regimens for amino acid compounds | US |
| 12364683 | Non-sedating dexmedetomidine treatment regimens | US |
| 12343381 | Dosage regimen for pegylated interferon | US |
| 12336980 | Dosing regimen for a selective S1P1 receptor agonist | US |
| 12138247 | Non-sedating dexmedetomidine treatment regimens | US |
| 12109196 | Non-sedating dexmedetomidine treatment regimens | US |
| 12090140 | Non-sedating dexmedetomidine treatment regimens | US |
| 12029788 | Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody | US |
| 11998528 | Non-sedating dexmedetomidine treatment regimens | US |
| 11998529 | Non-sedating dexmedetomidine treatment regimens | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of regimen?
regimen currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get regimen regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to regimen?
This spoke lists 52 published programs associated with regimen in our pipeline index.